Alpha Tau Medical (DRTS) Study update summary
Event summary combining transcript, slides, and related documents.
Study update summary
16 Nov, 2026Trial design and treatment
REGAIN is a prospective, open-label, single-arm study expanded from 10 to 20 patients; eight treated, with six reaching response assessment and planned 12-month follow-up.
Eligible patients have IDH wild-type grade 4 glioma, up to three recurrences and tumors under 3 cm; treatment uses image-guided stereotactic implantation of radium-224-loaded titanium sources.
Alpha DaRT uses radium-224 decay to release daughter atoms into tumors; alpha radiation acts independently of oxygen and causes double-strand DNA breaks, while particles travel 40–90 microns in tissue.
Interim efficacy and feasibility
Planned sources were deployed with tumor coverage in all treated patients; no unanticipated serious adverse events were reported.
All eight patients were alive at median follow-up of ~7 months; among six assessed, best response was five complete and one partial response, for a 100% overall response rate.
No recurrence was observed at treated sites; one progression occurred at a distant location. Response confirmation remains ongoing as additional scans are collected.
One grade 3 serious adverse event, a seizure with Todd's paralysis, resolved after rehabilitation and steroids; the patient returned to baseline.
Suspected necrosis or treatment changes were under evaluation in two patients and were asymptomatic; clinicians noted that later scans are needed to distinguish treatment effects from progression.
Follow-up and development plans
Enrollment is expanding across multiple sites, including NYU and Barrow; an additional interim GBM data update is expected when the first five patients complete six months, targeted for Q1 2027.
The study uses MRI and RANO for response assessment; amino acid PET is used at Ohio State to help evaluate ambiguous lesions, but is not standard across the trial.
FDA discussions continue on data maturity and a potential regulatory pathway; the study has Breakthrough Device Designation and is part of the Total Product Life Cycle Advisory Program.
Management expects Hudson, New Hampshire manufacturing capacity for commercial quantities by FDA approval; a focused launch strategy would target high-volume U.S. centers.
Latest events from Alpha Tau Medical
- Early clinical signals across four cancers support a broad Alpha DaRT pipeline.DRTS
Investor presentation - Strong clinical progress, U.S. partnership, and $104.8M cash drive expansion despite higher net loss.DRTS
Q2 2026 - Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained.DRTS
Lytham Partners Spring 2026 Investor Conference - Alpha DaRT shows promising efficacy in solid tumors, with pivotal trials and FDA submission expected by 2027.DRTS
Investor presentation - Q1 2026 featured breakthrough clinical results, pivotal trial progress, and a $22.9M net loss.DRTS
Q1 2026 - Interim data showed 67% complete response and strong safety in recurrent GBM.DRTS
Study result - Up to $300M in securities offered to fund Alpha DaRT cancer therapy R&D and commercialization.DRTS
Registration filing - Japan approval, pivotal U.S. trials, and strong data set up a transformative year.DRTS
Sidoti March Small-Cap Virtual Conference - Alpha DaRT shows promising efficacy in solid tumors, with pivotal trials and global expansion ongoing.DRTS
Investor presentation